BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30003323)

  • 1. Renal cell cancer after kidney transplantation.
    Kleine-Döpke D; Oelke M; Schwarz A; Schwager Y; Lehner F; Klempnauer J; Schrem H
    Langenbecks Arch Surg; 2018 Aug; 403(5):631-641. PubMed ID: 30003323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience.
    Santos SM; Carlos CM; Cabanayan-Casasola CB; Danguilan RA
    Transplant Proc; 2012 Jan; 44(1):154-60. PubMed ID: 22310603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK; Bhowmik D; Mahajan S; Bagchi S
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric renal transplantation: a single-center experience in northeast Thailand.
    Wisanuyotin S; Jiravuttipong A
    J Med Assoc Thai; 2009 Dec; 92(12):1635-9. PubMed ID: 20043566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.
    Thierry A; Le Meur Y; Ecotière L; Abou-Ayache R; Etienne I; Laurent C; Vuiblet V; Colosio C; Bouvier N; Aldigier JC; Rerolle JP; Javaugue V; Gand E; Bridoux F; Essig M; Hurault de Ligny B; Touchard G
    Transpl Int; 2016 Jan; 29(1):23-33. PubMed ID: 26729582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?
    Gigante M; Neuzillet Y; Patard JJ; Tillou X; Thuret R; Branchereau J; Timsit MO; Terrier N; Boutin JM; Sallusto F; Karam G; Barrou B; Chevallier D; Mazzola CR; Delaporte V; Doeffler A; Kleinclauss F; Badet L; ;
    BJU Int; 2012 Dec; 110(11 Pt B):E570-3. PubMed ID: 22726451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy.
    Demir T; Ozel L; Gökçe AM; Ata P; Kara M; Eriş C; Özdemir E; Titiz MI
    Transplant Proc; 2015 Jun; 47(5):1413-7. PubMed ID: 26093731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen.
    Geddes CC; Gunson R; Mazonakis E; Wan R; Thomson L; Clancy M; Carman WF
    Transpl Infect Dis; 2011 Apr; 13(2):109-16. PubMed ID: 21457419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up.
    Peres E; Abidi MH; Mellon-Reppen S; Klein J; Braun T; Abella E; Dansey R
    J Immunother; 2007; 30(5):562-6. PubMed ID: 17589297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation.
    Steubl D; Baumann M; Schuster T; Fischereder M; Krämer BK; Heemann U; Lutz J
    Scand J Urol Nephrol; 2012 Dec; 46(6):466-74. PubMed ID: 23016678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence.
    Pham PT; Pham PC
    Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
    Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutagenicity of immunosuppressive medications among renal transplant recipients.
    Rath T; Oliveira-Frick V
    Am J Nephrol; 2009; 30(6):514-20. PubMed ID: 19816013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.
    Barsoum RS; Morsey AA; Iskander IR; Morgan MM; Fayad TM; Atalla NT; Wafik H; Grace RA; Adel N; Khalil SS
    Exp Clin Transplant; 2007 Dec; 5(2):649-57. PubMed ID: 18194116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of azathioprine versus mycophenolate mofetil in cyclosporine-based immunosuppression in kidney transplantation: 10 years of experience at a single center.
    Kwon O; Cho JH; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transplant Proc; 2013 May; 45(4):1487-90. PubMed ID: 23726603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.